|Bid||0.1800 x 0|
|Ask||0.2200 x 0|
|Day's Range||0.1900 - 0.2000|
|52 Week Range||0.1700 - 0.9700|
|Beta (5Y Monthly)||-0.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
Insiders who bought CA$3.0m worth of Helix BioPharma Corp.'s ( TSE:HBP ) stock at an average buy price of CA$0.26 over...
VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp.
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.